Pediatrics expert available to comment on FDA approval of first OTC birth control pill

Tracey Wilkinson, an associate professor of pediatrics at the Indiana University School of Medicine, is available to comment on FDA approval of the first over-the-counter birth control pill. She was on the HRA Pharma (maker of the Opill) expert panel…

Annual Medicare spending could increase by $2 to $5 billion if Medicare expands coverage for dementia drug lecanemab

The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.

Medical experts available: OTC Narcan, Autism Acceptance Month and Black Maternal Health Week

Ochsner Health has medical experts on standby to discuss the groundbreaking FDA approval for over-the-counter Narcan for overdose, many topics related to autism as we promote Autism Acceptance Month in April, including signs of Autism in adults. Black Maternal Health…

Chula’s Engineering Develops Dynamic Prosthetic Feet with International Standards and 5 Times Less the Cost

Thailand now has 39,647 people with disabilities, over 95% of whom are using poor-quality prosthetic feet which are heavy and do not have ankles. This can adversely affect the way they walk, as well as their lives.

FDA Approves “Glowing Tumor” Imaging Drug to Aid Lung Cancer Surgery

The U.S. Food and Drug Administration has approved the targeted imaging agent Cytalux (pafolacianine) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors completely while sparing healthy tissue. Thoracic surgeons at the Center for Precision Surgery in the Abramson Cancer Center at Penn Medicine led the clinical trials evaluating the imaging agent in lung cancer, in a partnership with On Target Laboratories.

Thermedical Announces FDA Approval of Clinical Trial for SERF Ablation to Treat Patients with Ventricular Tachycardia, Leading Cause of Sudden Cardiac Death

WALTHAM, Mass., Aug. 23, 2022 – Thermedical®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an open-label, single-arm interventional clinical trial to evaluate the safety and efficacy of the Thermedical® SERF Ablation System with the Durablate® Catheter in people with ventricular tachycardia (VT) resistant to conventional treatment.

Increased Precision and Safety in Spinal Tap with PASS – An Ultrasound-Guided Lumbar Puncture Procedure

PASS (Point-Assisted Spinal Sonography), an ultrasound-guided lumbar puncture device from Chula doctors and engineers, helps increase the precision and confidence in spinal tap procedures while reducing risks and pain for patients.

Chula Researchers Find Extensive amounts of THC in Cannabis-Flavored Drinks The Public Is Cautioned and the Government Urged to Impose Stricter Control

Research work of a biochemistry expert at Chulalongkorn University finds that over 30% of cannabis-flavored drinks randomly tested contain higher THC levels than what is permitted. The public is warned to keep their consumption to moderate levels and that children should refrain from drinking this beverage. The government should control its consumption and warn the people of the benefit and harm of cannabis.

Penn Medicine Developed CAR T Cell Therapy Wins Third FDA Approval

The U.S. Food and Drug Administration (FDA) has expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The accelerated approval was granted today to Novartis for the chimeric antigen receptor (CAR) T-cell therapy Kymriah® (tisagenlecleucel), making it the third indication for the nation’s first personalized cellular therapy for cancer. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.

Light-Activated Dental Materials – the Latest Dental Innovation of International Standards from Chula

Chula Faculty members joined forces in dental materials science to develop easy-to-use “light-activated dental materials” that meet international standards and help shorten tooth filling time. The secret of these innovative dental materials, made by Thai people, is Acemannan polymer from Aloe Vera that can stimulate the formation of dentin and reduce tooth sensitivity in many dental health products.

Johns Hopkins Drug Commercialization Expert Looks at Controversy over Alzheimer’s Treatment

Johns Hopkins Carey Business School Senior Lecturer Supriya Munshaw – an expert in the commercialization of early-stage technologies, especially in the life science and medical device industries – offers her insights into the FDA’s rationale for approving the Alzheimer’s drug aducanumab, the price set by Biogen, the future of FDA leadership, and other related topics, in this Q&A.

Rutgers Pediatric Infectious Disease Expert Available to Discuss Pfizer’s Vaccine Approved by FDA for Children

Pediatric infectious disease expert David Cennimo is available to discuss the Food and Drug Administration approving Pfizer’s COVID-19 vaccine for emergency use on kids ages 12 to 15. “The Pfizer vaccine had a great track record of safety and success since…

Most dollars spent on top-selling orphan drugs don’t go to treat people with rare diseases

Pharmaceutical companies get special protection from the FDA for orphan drugs aimed at rare diseases, but a study shows high spending for common diseases for some such drugs. Just 21% of the total dollars spent in 2018 on 15 top-selling partial orphan drugs went to the treatment of rare diseases, while more than 70% went to the treatment of common diseases.

Seattle Cancer Care Alliance Selected as an Authorized Treatment Center for BreyanziTM/Liso-Cel CAR T-Cell Treatment

Seattle Cancer Care Alliance (SCCA), the only NCCN-designated cancer center in Washington State, has been selected as an authorized treatment center for the new chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel, also known as liso-cel and by the brand name BreyanziTM. Liso-cel was approved by the U.S. Food and Drug Administration (FDA) on February 5, 2021.

UCLA, UCSF gain FDA approval for prostate cancer imaging technique

The University of California’s two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and other parts of the body to which the tumors have migrated.

Rutgers Vaccine Expert Available to Discuss Moderna’s FDA Submission

Rutgers’ principal investigator for the Moderna phase 3 coronavirus vaccine clinical trial at Rutgers New Jersey Medical School is available to discuss the drugmaker’s submission of its vaccine to the U.S. Food and Drug Administration for regulatory approval. “It is…

Alzheimer’s Association should reveal financial conflict of interest in urging FDA to approve Biogen drug, says Dr. Leslie Norins, CEO of Alzheimer’s Germ Quest

Biogen tried, and failed, to win FDA committee approval for its anti-amyloid Alzheimer’s drug. The Alzheimer’s Association supported the application but did not reveal significant monies received from the firm.

Redesigning Hand Sanitizer and Donating 7,000 Gallons to Fight Covid-19

Notice how hand sanitizer has made a comeback? It was running out, but this charitable initiative helped revive it by tapping into ethyl alcohol and FDA approval.